Gold Fields Limited vs Twist Bioscience Corp — how do they compare? Gold Fields Limited trades at $42.71 (market cap $36.07B), while Twist Bioscience Corp trades at $123.98 (market cap $7.72B). The key difference: Gold Fields Limited is far larger — about 4.7× Twist Bioscience Corp's market cap, and Gold Fields Limited pays a 5.76% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GFI | TWST | |
|---|---|---|
Market Cap | $36.07B | $7.72B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $124.88 |
52-Week Low | $29.31 | $24.16 |
Enterprise Value | $37.51B | $7.65B |
Dividend Yield | 5.76% | — |
Signals from Pluang's Aura AI — not financial advice
Gold Fields Limited (GFI) trades at $41.12, up 0.73% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 40.76% net income margin and ROE of 52.33%, though recent quarterly earnings missed expectations. Revenue grew to $5.2B in 2024, with net income reaching $1.25B. Analyst consensus is a Buy with a $52 price target, indicating 26% upside potential.
The outlook for GFI is positive given its robust fundamentals and gold price tailwinds, but risks include volatile earnings performance and rising debt levels. Institutional accumulation and favorable sector sentiment support the bullish case, though investors should monitor cost pressures and execution on growth targets.
No Aura AI signal available yet.
Trailing returns across standard periods
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →